Scynexis, Inc. · NASDAQ:SCYX
Scynexis — Investor Presentation (October 2026)
23 slides from Scynexis's investor presentation, October 2026
Slide 1: Corporate Presentation
Corporate Presentation O U R M I S S I O N At SCYNEXIS, we are focused on advancing a portfolio of highly Advancing innovative solutions for severe differentiated, clinical-stage assets rare diseases targeting the underlying biology of severe rare diseases. OCTOBER 2026 NASDAQ: SCYX
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation has been prepared by SCYNEXIS, Inc. (the “Company”) solely for informational purposes. This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of applicable securities laws and ar
Slide 3: SCYNEXIS is Targeting the Underlying Biology of Severe Rare Diseases
SCYNEXIS is Targeting the Underlying Biology of Severe Rare Diseases • First-in-class, highly selective oral direct AMPK activator. FDA Orphan Drug Designation ADPKD • Favorable safety profile across 9 clinical trials covering ~300 participants (SCY-770) LEAD PROGRAM • Phase 2 PoC study on track for
Slide 4: Pipeline of Potential First-in-Class Products Targeting Rare Diseases
Pipeline of Potential First-in-Class Products Targeting Rare Diseases PROGRAM THERAPEUTIC AREA PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Autosomal Dominant Polycystic Kidney SCY-770 Disease (ADPKD) ORAL Phase 2 initiation by EOY Phase 2 interim analysis readout expected H2 2027 Treatment and Prevention of
Slide 5: ADPKD & SCY-770
ADPKD & SCY-770
Slide 6: ADPKD: Proven Demand, Unresolved Patient Need
ADPKD: Proven Demand, Unresolved Patient Need A blockbuster built on one available treatment, poorly tolerated >140K 50% $1.5B $192K U.S. PATIENTS END-STAGE KIDNEY DISEASE 2024 U.S. SALES ANNUAL LIST PRICE living with ADPKD, plus 6K new by age 60, driving ~5% of U.S. for Jynarque, with limited in 20
Slide 7: A Well-Characterized, Highly Selective Direct AMPK Activator
A Well-Characterized, Highly Selective Direct AMPK Activator INVESTMENT HIGHLIGHTS | SCY -770 IN ADPKD Novel mechanism Phase 2 ready Ready to dose Clear path Direct AMPK activator Favorable safety, well-characterized PK Oral formulation, robust CMC Clear regulatory route, IP to 2042 • Strong scienti
Slide 8: Reduced AMPK Activation in ADPKD Patients
Reduced AMPK Activation in ADPKD Patients Proximal Distal • ADPKD is a genetic disease caused by mutations of the Glomerulus tubule tubule PKD1 (85%) or PKD2 (15%) genes, which encode polycystin complex 1 (PC1) or polycystin complex 2 (PC2) proteins, critical for normal tubular epithelial cell funct
Slide 9: Mechanism of Action | SCY-770 in ADPKD
Mechanism of Action | SCY-770 IN ADPKD SCY-770 is a highly selective direct AMPK activator Preferential binding to β1-containing AMPK AMPK heterotrimers, most commonly present in the kidney In vitro activity of SCY-770 on recombinant AMPK proteins1 AMP Predominant in kidney Predominant in liver3 Pre
Slide 10: SCY-770 Works on Multiple Molecular Mechanisms in ADPKD
SCY-770 Works on Multiple Molecular Mechanisms in ADPKD | NASDAQ: SCYX | 10
Slide 11: SCY-770 – Demonstrated Robust in vivo Effects in ADPKD Mice
SCY-770 – Demonstrated Robust in vivo Effects in ADPKD Mice Reduced cyst formation and impact on renal function Tamoxifen-inducible kidney epithelium–specific Pkd1 deletion (Ksp-TamCre x Pkd1Lox), mice sacrificed when blood urea level was ≥ 20mM (ESRD) and study was terminated when 50% of control mi
Slide 12: SCY-770 Development Plan
| a SCY-770 Development Plan
Slide 13: SCY-770 Illustrative Path Forward
SCY-770 Illustrative Path Forward Phase 1* Phase 2 EoP2 FDA Phase 3 Interim Analysis (htTKV) 12-months 24-month htTKV eGFR NDA sNDA htTKV = measures the kidney volume changes via MRI eGFR = measures the kidney function changes Phase 1* (exposure and food effect at doses intended for Phase 2); comple
Slide 14: SCY-770 Phase 1: Well-Tolerated with favorable safety profile
SCY-770 Phase 1: Well-Tolerated with favorable safety profile Phase 1 results support dose selection for the Phase 2 proof-of-concept study in ADPKD OBJECTIVE STUDY DESIGN RESULTS Assess safety and tolerability healthy participants in 3 cohorts, in healthy adults at doses higher than previously eval
Slide 15: Invasive Fungal Infections & SCY-247
Invasive Fungal Infections & SCY-247
Slide 16: Addressing the Limitations of Current Antifungal Therapies
Addressing the Limitations of Current Antifungal Therapies Two large, underserved markets. One differentiated therapy TREATMENT OF INVASIVE CANDIDIASIS PROPHYLAXIS OF IFD A market defined by high mortality and growing resistance Long-duration therapy in large at-risk populations ~70K 20–40% U.S. CAS
Slide 17: SCY-247: Our Next-Generation Fungerp
SCY-247: Our Next-Generation Fungerp Multiple attributes translate the fungerp mechanism into a commercially viable profile — engineered around flexibility in clinical delivery, tissue distribution, and activity against resistant strains Broad Low DDI Tissue Favorable IV + Oral Spectrum Risk Distrib
Slide 18: Financial Update & Outlook
Financial Update & Outlook
Slide 19: Financial Snapshot
Financial Snapshot Capital Structure and Financials Outstanding Shares & Pre-funded Warrants Cash and Runway Common Shares1 9,949,609 Total Cash2 $71.1M Pre-funded Warrants 1,892,471 Debt Outstanding None Total 11,842,080 Runway Into 2029 1. Common shares outstanding as of Sep 30, 2026. 2. Cash, cas
Slide 20: Capital Efficiency Through Non-Dilutive R&D Funding
Capital Efficiency Through Non-Dilutive R&D Funding BARDA CONTRACT NO. 75A50126C00007 · ANNOUNCED SEPT 28, 2026 · SCY-247 BARDA CONTRACT VALUE, IF ALL OPTIONS ARE EXERCISED Non-dilutive funding advances SCY-247 from its current stage through NDA submission: Up to $214 million Preserving shareholder
Slide 21: Multiple Value-Enhancing Milestones Expected
Multiple Value-Enhancing Milestones Expected 2026 2027 2028 Initiation of Phase 2 Phase 2 study Phase 1 data Phase 2 study Interim Analysis completion Oct 2026 Q4 2026 2H 2027 2H 2028 SCY-770 ADPKD Initiation of Phase 2 IV Phase 1 data Study Oct 2026 2027 SCY-247 ANTIFUNGAL | NASDAQ: SCYX | 21
Slide 22: A Compelling Investment Opportunity in Severe Rare Disease
A Compelling Investment Opportunity in Severe Rare Disease Experienced leadership with a proven track record of drug approvals, regulatory success and asset monetization CASH, CASH EQUIVALENTS & INVESTMENTS CASH RUNWAY NASDAQ $71.1M into 2029 SCYX as of June 30, 2026 clinical-stage biotech LEAD PROG
Slide 23: Thank You
Thank You NASDAQ: SCYX